fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

FDA approves Kerendia in chronic kidney disease (CKD) associated with type 2 diabetes – Bayer HealthCare

Written by | 21 Jul 2021

Bayer announced the FDA has approved Kerendia (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR decline, kidney failure, cardiovascular death,… read more.

Positive new data for Johnson & Johnson single-shot COVID-19 vaccine on activity against Delta variant and long-lasting durability of response

Written by | 18 Jul 2021

Johnson & Johnson announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants…. read more.

UK MHRA approval for Byfavo for procedural sedation – Paion AG

Written by | 17 Jul 2021

PAION AG announces that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has approved Byfavo (remimazolam besylate) in adults for procedural sedation. Byfavo is an ultra-short-acting intravenous… read more.

FDA grants regular approval and expands indication for Padcev for patients with locally advanced or metastatic urothelial cancer

Written by | 16 Jul 2021

Seagen Inc. and Astellas Pharma Inc. announced the FDA granted Padcev (enfortumab vedotin-ejfv) regular approval in the U.S., in addition to approving a new indication for adult patients… read more.

Diurnal receives marketing authorisation for Efmody to treat congenital adrenal hyperplasia from the MHRA (UK)

Written by | 15 Jul 2021

Diurnal Group plc announces that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a Marketing Authorisation for Efmody (hydrocortisone modified-release hard capsules – development name… read more.

Advicenne receives MHRA approval to market Sibnayal in the UK for the treatment of distal renal tubular acidosis

Written by | 14 Jul 2021

Advicenne announces that the Medicines & Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Sibnayal (ADV 7103) in the UK, for the treatment of distal renal… read more.

Hansa Biopharma announces long term follow-up data demonstrating 3-year graft survival of 84% after imlifidase treatment and transplantation

Written by | 13 Jul 2021

Hansa Biopharma, announced three-year follow-up data in crossmatch positive patients who received imlifidase prior to kidney transplantation. As reported in an article, which has been accepted for publication… read more.

FDA approves expanded label for Keytruda for locally advanced cutaneous squamous cell carcinoma that is not curable by surgery or radiation – Merck Inc.

Written by | 12 Jul 2021

Merck has announced that the FDA has approved an expanded label for Keytruda, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with locally advanced cutaneous squamous… read more.

Merck Inc provides update on Keytruda indication in third-line gastric cancer in the US

Written by | 11 Jul 2021

Merck announced that the company plans to voluntarily withdraw the U.S. accelerated approval indication for Keytruda for the treatment of patients with recurrent locally advanced or metastatic gastric… read more.

FDA approves Solosec for trichomoniasis in adults – Lupin Pharma

Written by | 10 Jul 2021

Lupin Pharmaceuticals announced that the FDA has approved the company’s supplemental New Drug Application (sNDA) to expand the use of Solosec (secnidazole) to include the treatment of trichomoniasis… read more.

Philips announces first patient treated with its new real-time 3D intracardiac echocardiography catheter – VeriSight Pro

Written by | 9 Jul 2021

Royal Philips announced FDA 510k-clearance of real-time 3D intracardiac echocardiography (ICE) VeriSight Pro catheter which has the potential to improve standard of care for structural heart disease and… read more.

New Soliqua data shows improved blood sugar control without weight gain versus premixed insulin – Sanofi

Written by | 9 Jul 2021

A new study of Soliqua (insulin glargine 100 Units/mL and lixisenatide, (iGlarLixi) met its two primary endpoints and all key secondary endpoints in a head-to-head comparison against premixed… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.